KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Receivables - Other (2020 - 2023)

Pfizer (PFE) has disclosed Receivables - Other for 8 consecutive years, with $57.0 million as the latest value for Q2 2023.

  • Quarterly Receivables - Other fell 57.14% to $57.0 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $57.0 million through Apr 2023, down 57.14% year-over-year, with the annual reading at $53.0 million for FY2021, 86.78% down from the prior year.
  • Receivables - Other for Q2 2023 was $57.0 million at Pfizer, down from $167.0 million in the prior quarter.
  • The five-year high for Receivables - Other was $871.0 million in Q2 2021, with the low at $53.0 million in Q4 2021.
  • Average Receivables - Other over 4 years is $287.2 million, with a median of $197.0 million recorded in 2021.
  • The sharpest move saw Receivables - Other tumbled 86.78% in 2021, then dropped 15.23% in 2022.
  • Over 4 years, Receivables - Other stood at $401.0 million in 2020, then crashed by 86.78% to $53.0 million in 2021, then surged by 215.09% to $167.0 million in 2022, then tumbled by 65.87% to $57.0 million in 2023.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $57.0 million, $167.0 million, and $272.0 million for Q2 2023, Q4 2022, and Q3 2022 respectively.